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Summary 
Human interleukin 1/$ (IL-1B) is synthesized as an inactive precursor that is cleaved by IL-1 
converting enzyme (ICE) between Asp  116 and Ala 11y to form COOH-terminal mature IL-1/3 
and NH2-terminal  IL-1B propeptide. Little is known about the fate of the NH2-terminal cleavage 
product. In this study, human recombinant (hr)IL-1/3 propeptide (amino acids 2-116) was produced 
and used to prepare  specific antibodies which do not recognize mature human IL-1B.  These 
anti-propeptide antibodies were used for immunoprecipitation  of biosynthetically labeled proteins 
from lipopolysaccharide-stimulated human monocytes. Analysis of immunopredpitates by sodium 
dodecyl sulfate-polyacrylamide  gel electrophoresis and fluorography revealed that these antibodies 
recognize precursor IL-I~ and two unique proteins: one migrating at 17.5 kD and one at 14 kD. 
The larger of these two proteins has a migration nearly identical to that of the recombinant 
IL-1/3 propeptide, and most likely represents naturally derived propeptide. The protein migrating 
at 14 kD may result from a second cleavage by ICE, between Asp  27 and Gly  2s. These proteins 
accumulate intracellularly and extracellularly during pulse-chase experiments, and therefore represent 
stable products of precursor IL-1B cleavage. 
H 
uman (hlblB) 1 IL-IB is synthesized as a 35-kD inac- 
tive precursor protein (1-4) and is cleaved to release the 
COOH-terminal portion of the molecule, mature 17.5-kD 
IL-1/3, which possesses all the known activities  of IL-1B. 
Precursor IL-1B may be cleaved by a variety of proteases (3, 
4) to give products with partial activity,  but full activity is 
produced only by cleavage between Asp  116 and Ala tit by the 
newly discovered  IL-1B  converting enzyme (ICE)  (5,  6). 
Stimulated human monocytes synthesize large amounts of 
both precursor IL-1B and ICE (7, 8), and produce most of 
the circulating mature IL-1B present in humans. 
Ahhough mature IL-1/3 has been the subject of exhaus- 
tive research,  surprisingly little attention has been paid to 
the NH2-terminal product of precursor IL-1B cleavage, the 
IL-1/3 propeptide. One previous study using antibodies directed 
against short synthetic peptides from the propeptide region 
(9) failed to demonstrate the presence of intact propeptide 
in human monocytes induced to synthesize and process IL- 
lB.  Other  studies of IL-1B  processing (10-14)  have used 
antibodies made against mature IL-1B or peptides from the 
1Abbreviations  used in  this paper:  hr,  human recombinant; ICE,  IL-1B 
converting enzyme; hlL-1/3, human interleukin-lO; IPTG, isopropyhhio- 
galactoside; MBP, maltose binding protein; PGS, protein G-Sepharose. 
COOH-terminal  region,  and  therefore would not  detect 
the propeptide. These results have led to the assumption 
that the NH2-terminal propeptide is rapidly degraded after 
specific cleavage to precursor IL-13 by ICE. To the contrary, 
we show that intact IL-13 propeptide is present in significant 
amounts in LPS-stimulated human peripheral blood mono- 
cytes in vitro and, like mature IL-13, is released into the cul- 
ture medium. 
Materials and Methods 
Production  ofrlLl~SPropeptide  A eDNA clone  encoding  the com- 
plete amino acid sequence  of precursor Ibl/3 was supplied  by Up- 
john Pharmaceuticals  (Kalamazoo, MI). A DNA fragment encoding 
the IL-1/3  propeptide was produced by PCR (15) using the primers 
GCAGAAGTACCTGAGCT  (corresponding  to nudeotides 4-21 of 
the coding strand) and CGAATTCTTAATCGTGCACATAAGCCT 
(corresponding to nucleotides 331-348 of the noncoding strand, 
with a noncomplementary  extension for a translation termination 
codon followed  by an EcoRI site.) The PCK product was cut with 
EcoKI, isolated  by electroelution from agarose gel electrophoresis, 
and ligated in the pMal-c expression  vector (16) (New England Bio- 
Labs, Beverly,  MA) between StuI and EcoKI sites in the polylinker 
region. Products of the ligation reaction were transformed into 
Escherichia coli TB1. A positive clone  with a DNA sequence  iden- 
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pressed a fusion protein consisting of the maltose binding protein 
(MBP) of E. coli, the factor Xa cleavage site, and II.-l~ propeptide 
(amino acids 2-116). (The NH2-terminal amino acid residue of nat- 
ural precursor IL-1/3 is not known. We chose to omit the NH2- 
terminal methionine, because the NH2-termini of most cytosolic 
proteins with alanine as the second amino acid are posttranscrip- 
tionally modified  by cleavage  of methionine [18]. In any event, this 
decision is not relevant to the results of this paper.) 
Synthesis of the fusion protein (MBP-II~I/~  propeptide) was in- 
duced by treatment of  bacterial suspension  with 3 mM isopropylthio- 
galactoside (IFIG) for 2 h. The bacteria were collected  by centrifu- 
gation, and bacterial extract was prepared by resuspension in lysis 
buffer (15 mM sodium phosphate, 30 mM NaC1, 25 mM benzami- 
dine, I mM PMSF, 1 mM EDTA, 0.2% Tween-20, pH 7.3) con- 
taining 4 mg/ml lysozyme (Boehringer Mannheim Biochemicals, 
Indianapolis, IN), followed by sonication. The sonicated suspen- 
sion was then brought to 0.5 M NaC1, and 5 #g/ml DNAase-free 
KNAase was added. After removal of particulate material by cen- 
trifugation at 50,000g for 30 rain at 4~  the extract was applied 
to amylose resin (New England Biolabs). The resin was washed 
with 10 volumes of 20 mM sodium phosphate, 200 mM NaC1, 
i mM PMSF, pH 7.4, and fusion protein was eluted with 10 mM 
maltose in 20 mM "Iris, 100 mM NaC1, pH 8.0. When indicated, 
fusion protein was digested overnight at 4~  with 1 #g of Factor 
Xa protease (New England Biolabs) per 100 #g of fusion protein, 
to produce MBP and IL-lfl propeptide. 
Amino Acid Sequencing.  Fusion  protein was concentrated using 
Centricon-10 ultrafiltration device (Amicon Corp., Beverly,  MA), 
digested with Factor Xa, electrophoresed  on a 14% polyacrylamide 
SDS gel (19), and transferred to a PVDF membrane. The band cor- 
responding to IL-I~ propeptide was cut out and analyzed  by NH2- 
terminal amino acid sequencing using a pulse liquid-vapor phase 
protein sequencer (model 477A; Applied Biosystems  Inc., Foster 
City, CA). 
Antibodies.  Rabbit  anti-human rlL-1/5 (mature IL-I~, IgG frac- 
tion, was purchased from Upstate Biotechnology,  Inc. (Lake  Placid, 
NY). Antibodies  against IL-1/~  propeptide were produced as follows: 
rabbits were first immunized with 500 #g of MBP-IL-lfl propep- 
tide fusion protein in CFA. For subsequent immunizations, factor 
Xa digests of fusion protein were separated by SDS-PAGE on 1.5- 
mm-thick gels. To rapidly visualize  protein bands, gels were soaked 
in distilled water at 23~  for 15 min, and then in 2 M KC1 at 
4~  for 15 rain. The band corresponding to Ibl/3 propeptide (seen 
as cloudy against a dear background) was cut out and electroeluted, 
and then emulsified  in IFA. The antiserum produced in this manner 
recognized both MBP and IL-I~ propeptide, but since there is no 
correlate of MBP in mammalian cells, this specificity  is irrelevant. 
For production of anti-peptide antibodies, peptides corresponding 
to amino acids 1-27, 28-57, 58-87, and 88-116 of the IL-1B  propep- 
tide sequence were produced by the technique of Merrifield (20) 
using a peptide synthesizer from Applied Biosystems,  Inc. (Model 
430). Peptide-KLH conjugates were made by mixing peptide and 
KLH (Sigma Chemical Co., St. Louis, MO), both 0.5 mg/ml in 
0.1 M NaHCO3/Na2CO3 buffer, pH 8.5, with 1.25% glutaralde- 
hyde at 23~  for 48 h, followed  by exhaustive  dialysis  against water, 
and then against PBS. Rabbits were immunized with 200/xg of 
individual peptide-KLH  conjugates in  CFA, followed by two 
boosters of conjugate in IFA. Only immunization with peptides 
28-57 and 88-116 resulted in production of antibodies that were 
usable for Western blot and immunoprecipitation. IgG from rabbit 
antisera was  prepared by  adsorption  to  recombinant  protein 
A-Sepharose 4B (Zymed Laboratories, Inc., South San Francisco, 
CA) and elution at neutral pH (ImmunoPure Gentle Ag/Ab Buffer 
System  from Pierce, Rockford, IL), followed  by exhaustive  dialysis. 
Western Blots.  hrlL-1/~  was kindly donated by Upjohn Phar- 
maceuticals. Factor Xa digests of MBPqbl/5 propeptide were pre- 
pared as described above. Samples were electrophoresed on 14% 
acrylamide  SDS gels and electrophoretically  transferred to nitrocel- 
lulose membranes (Trans-blot System from Bio-Rad Laboratories, 
Hercules, CA).  Prestained molecular weight  markers (Bio-Rad 
Laboratories) were used. Blots were blocked overnight with 3% 
gelatin (Bio-Rad  Laboratories)  in TBS (20 raM Tris, 500 mM NaC1, 
pH 7.5), and then incubated with the indicated primary rabbit an- 
tibody in 1% gelatin-TTBS  (TBS with 0.05% Tween-20), washed 
in TTBS, and incubated with 1/3,000 goat anti-rabbit IgG alka- 
line phosphatase conjugate (Bio-Rad Laboratories) in 1% gelatin- 
TTBS. Blots were then developed  by adding substrate solution con- 
sisting of 132 #1 of p-nitroblue tetrazolium chloride (50 mg/ml 
in 70% dimetbylformamide) and 66/zl of 5-bromo-4-chloro-3- 
indolyl phosphate (50 mg/ml in dimetbylformamide) per 20 ml 
of 100 mM "Iris, 100 mM NaCI, 5 mM MgC12, pH 9.5. 
Isolation and Biosynthetic Labeling of  Human Monofftes.  Leukocyte- 
rich plasma was prepared from peripheral blood of normal human 
volunteers by anticoagulation with 3 mM EDTA and removal of 
erythrocytes by 1 g sedimentation for 60 rain in 0.6%  dextran. 
Monocytes were then separated from the remainder of the leuko- 
cytes by density gradient centrifugation on 1-Step Monocytes (Ac- 
curate Chemical & Scientific  Corp., Westbury, NY), according to 
the manufacturer's directions. The calls obtained by this method 
were >99% monocytes by Wright stain and >98% viable by ex- 
clusion of 0.1% trypan blue. Monocytes were washed twice and 
suspended at  106  cells/ml in culture  medium (methionine-free 
RPMI-1640 plus 2 mM L-glutamine,  100 U/m1 penicillin, 100 #g/m1 
streptomycin, and 2% heat-inactivated  autologous human serum). 
LPS (10 gg/ml) from E. coli serotype  055:B5 (Sigma  Chemical Co.) 
and 100 #Ci/ml [3SS]methionine  and [3SS]cysteine  (Expre~SS3sS pro- 
tdn  labeling mix,  >1,000 Ci/mmol,  New  England  Nuclear- 
DuPont, Wilmington, DE) were added, and cells were cultured 
for 4 h at 37~  Virtually all the monocytes adhered to the tissue 
culture vessel. 
For pulse-chase experiments, LPS-stimulated  human monocytes 
were biosynthetically  labeled  as above, washed  with culture medium 
containing unlabeled methionine, and cultured for an additional 
4 h in culture medium containing unlabeled methionine and 10 
#g/ml LPS. Replicate cultures were harvested at various intervals. 
Immunoprecipitation of Culture Sut,ematants and Cell Lysates.  After 
4 h, culture supematant was collected and the adherent cells were 
washed once with fresh culture medium. The culture supematant 
and wash were pooled and centrifuged at 600g for 10 min at 4~ 
to remove  any monocytes  that may have  become  nonadberent. PMSF 
and benzamidine were added to achieve final concentrations of 1 
and 25 mM, respectively, and the culture supematant was then 
centrifuged at 30,000 g for 30 rain at 4~  Adherent cells were 
lysed by addition of ice-cold lysis buffer (50 mM "Iris, 150 mM 
NaCI, 1 mM PMSF, 25 mM benzamidine, 1% NP-40, pH 7.5), 
followed by incubation at 4~  for 30 rain. Cell lysate was cen- 
trifuged at 30,000 g for 30 rain at 4~  Samples were stored over- 
night at  -70~  quickly thawed at 37~  and chilled on ice. All 
subsequent immunoprecipitation and washing operations were car- 
ried out at 4~  In some experiments described but not shown, 
a mixture of five additional protease inhibitors was added to the 
culture supematants and cell lysis  buffer (final  concentrations 1 mM 
EDTA, 10 mM N-ethylmaldmide,  1 ttg/ml leupeptin, 1 #g/ml 
pepstatin, and 1 ttg/ml aprotinin). 
Culture supernatants and cell lysates were cleared of IgG from 
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100/A per 5 ml of sample) of recombinant  protein  G-Sepharose 
4B beads (PGS) (Zymed Laboratories,  Inc.).  Samples were cen- 
trifuged  at 50 g for 5 rain to remove the beads, and then divided 
into the desired number of equal aliquots.  Supernatants  and cell 
lysates representing  equal numbers  of cells, usually between 0.5 
x  106 and 1  x  106, were used for immunoprecipitation with each 
different antibody. The IgG fractions of rabbit antisera, purchased 
or prepared as described above, were individually titered  for use 
in immunoprecipitation. 
For competition  studies, a limiting  amount of antibody was 
added. For all other studies, antibody was added in approximately 
fivefold excess of the amount needed to precipitate the maximal 
amount  of radiolabeled  Iblfl  moieties.  At  fivefold excess, the 
effidency of immunoprecipitation for all the antibodies, determined 
by repeating the same immunoprecipitation on the supernatant from 
the first immunopredpitation,  was between 80 and 85%. How- 
ever, antibody against IL-lfl propeptide  consistently  precipitated 
more precursor Iblfl, on both the first and second immunoprecipi- 
tations,  than  did antibody against mature IL-1/3. 
Each aliquot of culture supernatant or cell lysate was incubated 
for 1 h with the indicated antibody, and then tumbled for 90 min 
with 40/~1 of fresh PGS beads. The beads were collected by cen- 
trifugation  at 50 g for 3 min and were washed three times with 
wash buffer A (10 mM Tris, 500 mM NaC1, 2 mM EDTA, 1 mM 
PMSF, 0.2% NP-40, pH 7.5), two times with wash buffer B (same 
as A but with 150 mM NaC1), and once with 10 mM Tris, 1 mM 
PMSF, pH 7.5, taking care not to lose beads when aspirating the 
wash solutions. The PGS was ehted twice with 40 gl of sample 
buffer for SDS-PAGE (19) for 10 rain at room temperature,  and 
ehates were pooled and frozen overnight  at  -70~ 
SDS-PAGE and Detection of Labeled Proteins.  The entire [3sS]- 
methionine-labded  eluate  from  each  immunoprecipitation  was 
applied to 14% polyacrylamide SDS gels for electrophoresis. Mo- 
lecular weight standards from Bio-Rad  Laboratories were used. 
Gels were stained with Coomassie Blue, impregnated  with fluor 
(En3Hance; New England  Nudear-DuPont) according to manu- 
facturer's directions, dried, and exposed to X-Omat AR film (Kodak, 
Rochester, NY) for the indicated times. For some experiments, gels 
were dried without impregnation  with fluor and analyzed using 
a Molecular Dynamics Phosphorlmager,  which allowed quantita- 
tion  of  bands  but  did  not  produce  images  acceptable for 
reproduction. 
Results 
Production and Enzymatic Cleavage of Fusion Protein.  The 
recombinant fusion protein MBP-IL-lfl propeptide was ex- 
pressed in large amounts in induced E. coli and rendered sub- 
stantially free of contaminating  bacterial proteins or degra- 
dation products by amylose affinity chromatography. A typical 
preparation,  analyzed by SDS-PAGE  and  Coomassie Blue 
staining,  is shown in Fig.  1 A.  The heavy band migrating 
at approximately 60 kD in SDS-solubilized induced E.  coli 
(lane 2) is the fusion protein,  which is absent from unin- 
duced bacteria  (lane  1).  This  fusion  protein  was partially 
purified from bacterial extracts by selectively binding to amy- 
lose and during with maltose (lanes 3-I0). Typical yields from 
this procedure were 3 to 6 mg of fusion protein per liter of 
induced E. coli suspension. As shown in Fig.  1 B, digestion 
of this product  with  Factor Xa produced maltose binding 
protein, migrating at ~38 kD, IL-lfl propeptide, migrating 
at '~17.5 kD, and some residual undigested fusion protein. 
Although the apparent molecular weight of the IL-lfl propep- 
tide was large~ than expected, its identity was verified by DNA 
sequencing of the expression vector (21) and amino acid se- 
quencing of the first  10 NH2-terminal  amino acid residues 
of the  17.5-kD band. 
Specificity of  Antibodies.  The specificity of rabbit polyclonal 
antibodies produced against hrIL-lfl propeptide (amino acids 
2-116), and against smaller synthetic peptides of this protein, 
was checked by Western blotting,  as described in Materials 
and Methods and shown in Fig. 2.  Commercially obtained 
rabbit polyclonal antibody against  hrIL-lfl  (mature  IL-lfl, 
amino acids 117-269) detected mature IL-lfl (lane I), but not 
hrlL-lfl  propeptide  prepared  by digestion  of MBP-IL-lfl 
propeptide with Factor Xa (lane 2). Antibody prepared against 
MBP-IL-lfl  propeptide did not  detect mature  IL-lfl  (lane 
3), but did detect IL-1B propeptide,  maltose binding pro- 
tein,  and undigested fusion protein  (lane 4). A  mixture  of 
antibodies against IL-lfl synthetic peptides 28-57 and 88-116 
detected only hrIL-lfl propeptide and undigested fusion pro- 
tein (lane 6). This blot also demonstrates that the migration 
of hrIL-lfl propeptide is only slightly faster than that of the 
Figure 1. SDS-PAGE  of MBP- 
Iblfl propeptide fusion protein 
preparation and  digestion with 
Factor Xa. (A) Lanes  I and2 show 
the induction of MBP-II~IB fu- 
sion protein  in transformed  E. coli 
by IF~. Lane I is uninduced, and 
hne 2 is IFl~induced whole  bac- 
teria solubilized  by boiling  in SDS. 
The bacterial extract of induced 
E. coli (lane 3) prepared by lyso- 
zyme  treatment and detergent  and 
hypotonic lysis, was subjected  to 
amylose  atfinity  chromatography. 
Lanes 4-10 show sequential frac- 
tions obtained by elution of the 
amylose  column  with maltose. (B) 
Treatment with factor  Xa overnight at 4~  resulted  in almost complete  digestion of  fusion protein to give  MBP (38 kD) and Iblfl propeptide (17.5 kD). 
Gels are: A,  12% acrylamide; and B, 15% acrylamide, stained with Coomassie Blue. 
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the IL.1/~  precursor molecule. Rabbit polyclonal antibodies against either 
mature IL-1B  (lanes 1 and 2), MBP-IL-1B  propeptide fusion protein (lanes 
3 and 4), or IL-1B  synthetic peptides (amino acids 28-57 and 88-116) (lanes 
5 and 6) at 1/500 dilutions  were used to probe this blot.  The antigen 
in lanes 1, 3, and 5 was 100 ng of commercially obtained hrlIr  (mature, 
amino acids 117-269) and in lanes 2, 4, and 6, 300 ng of Factor Xa digest 
of fusion protein  (MBP-IL-1B  propeptide  amino acids 2-116) containing 
,~100 ng of propeptide. 
17.5-kD hrlL-lfl. The lowest prestained marker, lysozyme, 
is said to migrate at 18.5 kD (Bio-Rad Laboratories, package 
insert),  but its migration is anomalous with respect to the 
known migration of mature IL-lfl, and with respect to un- 
modified molecular weight markers  (not shown). 
Detection of IL-I~ Propeptide  from LPS-stimulated Human 
Monocytes.  Human peripheral blood monocytes were stimu- 
lated with LPS and biosynthetically  labeled with [3SS]me- 
thionine-cysteine  mix. Proteins recognized by antibody against 
mature IL-1/~, MBP-hrlL-1/3 propeptide, and IL-lfl synthetic 
peptides were isolated by immunoprecipitation. The entire 
sample from each immunoprecipitation was analyzed by SDS- 
PAGE and fluorography. As shown in Fig. 3, the major in- 
tracellular precursor form of IL-lfl migrated at m35 kD. Mul- 
tiple smaller bands between 29-35 kD were seen, comparable 
to other reports  (11, 13). Precursor I1-1/5 was also found, in 
smaller amounts, in culture media, mainly as the 35-kD form 
(lanes I-3).  In  subsequent  experiments  (not  shown),  the 
amount of precursor in the culture media could be reduced, 
but not entirely eliminated,  by more thorough removal of 
cells from the media before the second, high speed, centrifu- 
gation. Others have also demonstrated the apparent  secre- 
tion of precursor IL-I~ (9, 11, 13, 14). Mature 17.5-kD IL- 
1B was present largely as a secreted  product (lane 3), although 
some was observed in cell lysates (lane 6). The apparent reten- 
tion of a small amount of mature IL-1/3 intracellularly  by 
human monocytes has been shown in previous reports (11, 
13, 14). An artifact, such as continued activity of ICE after 
cell lysis, or sticking of processed IL-1/3 to the plasma mem- 
brane before lysis, has not been entirely ruled out. 
The observation unique to this report is that two proteins 
are recognized by specific antibodies  against IL-I~ propep- 
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Figure  3.  SDS-PAGE  and fluorography of biosynthetically labeled pro- 
teins from LPS-stimulated human monocytes, immunoprecipitated  with 
antibodies specific for different portions  of the I1.-13 precursor molecule. 
Culture supernatant (lanes I-3) and cell lysate (lanes 4-6) were immuno- 
precipitated with rabbit antibody against Ibl3 synthetic peptides (amino 
acids 28-57 and 88-116) in lanes 1 and 4, against MBP-IL-13 propeptide 
(amino acids 2-116) in lanes 2 and 5,  and against  mature  IL-13 (amino 
acids 117-269) in lanes 3 and 6. This gel was exposed to film for 3 wk. 
tide and its smaller synthetic peptides (Fig. 3, lanes 1, 2, 4, 
and  5).  Based  on  the  unusually  slow  migration  of  the 
115-amino acid recombinant propeptide (Fig. 2), the band 
with mobility virtually identical to that of mature 17.5-kD 
IL-13 (Figs. 2 and 3) appears to be the naturally produced 
IL-lfl propeptide. A second band migrating at ,v 14 kD, also 
immunoprecipitated by the anti-propeptide antibodies, is evi- 
dent in Figs. 3 and 4. As shown in Fig. 4, antibody against 
amino acids 28-57, and antibody against amino acids 88-116 
of the propeptide sequence, both precipitate this band in ap- 
proximately  equal amounts. The presence of epitopes from 
these two noncontiguous portions of the precursor suggests 
that this protein may be a result of cleavage near the amino 
terminus of the 17.5-kD propeptide. This 14-kD protein may 
result from further processing of the propeptide at a second 
site,  Asp27-Gly  2s,  characterized  previously  using  highly 
purified  ICE and synthetic peptides  (22). 
As shown in Fig. 3, the IL-1/3 propeptide moieties were 
found both extracellularly (lanes 1 and 2) and intracellularly 
(lanes 4 and 5).  The relative proportions of the 17.5- and 
14-kD propeptide moieties varied somewhat among mono- 
cytes from several individual donors, but was consistent for 
each individual in separate experiments. In general, however, Figure  4.  Immunoprecipita- 
tion of the 14-kD secreted propep- 
tide moiety by antibodies against 
synthetic  peptides  representing 
two different portions of the Ib 
1/3  propeptide  amino  acid  se- 
quence. Culture supernatant from 
LPS-stimuhted  human  mono- 
cytes,  biosynthetically  labded 
with  [3SS]methionine, was  im- 
munoprecipitated  with antibody 
against Iblfl synthetic peptides or 
mature  IL.I~. The immunopre- 
cipitated material was analyzed by 
SDS-PAGE  and fluorography. An- 
tibodies  were  as  follows:  anti- 
synthetic peptide 28-57 (lane 1), 
anti-synthetic  peptide 88-116 (lane 2), equal amounts of these two anti- 
bodies combined (lane ./),  and anti-mature  Ibl~ (amino  acids 117-269) 
(lane 4).  This gel was exposed to film for 1 wk. 
the 14-kD propeptide moiety predominated in culture su- 
pernatants, while the 17.5- and 14-kD propeptide moieties 
were usually present in approximately equal amounts in cell 
lysates. 
Competition by  Unlabeled Mature IL-1fl and MBP-IL-I~ 
Propeptide.  Although specificity of the antibodies used for 
these experiments was demonstrated by Western blot, we 
wished to demonstrate that they were specific for the rele- 
vant native,  as well as denatured, proteins. For the experi- 
ment shown in Fig.  5, biosynthetically labeled culture su- 
pernatant from LPS-stimulated monocytes was divided into 
equal aliquots, which then received either no addition, unla- 
beled  hrlL-lfl  (mature  IL-I~),  or  unlabeled MBP-IL-lfl 
propeptide. Limiting quantities of antibody against either ma- 
ture I1-18 or I1-18 propeptide were added, and immunopre- 
cipitation was carried out as usual. As expected, unlabeled 
mature IL-13 (lane 5), but not unlabeled MBP-IL-13 propep- 
tide (lane 6), competed for binding of labeled mature IL-13 
and precursor IL-13 to anti-mature I1-18. Conversely, unla- 
beled MBP-IL-13 propeptide (lane 3) but not unlabeled ma- 
ture IL-13 (lane 2) competed for binding of labeled  IL-13 
propeptide and precursor IL-13 to antibody against IL-13 
propeptide. In experiments not shown, unlabeled recombinant 
MBP did not compete out any of the IL-13 bands. There- 
fore, the 17.5- and 14-kD bands immunoprecipitated with 
antibodies against IL-13 propeptide are not related  to ma- 
ture IL-13, and represent authentic IL-13 propeptide moie- 
ties.  In  the  experiment shown,  mainly the  14-kD  IL-13 
propeptide was found in the culture supernatant. Longer ex- 
posure (not shown) was required to detect the 17.5-kD propep- 
tide, which was competed out as described above. 
The decreased ability of anti-mature IL-13 to immuno- 
precipitate the 35-kD precursor IL-13 was especially notice- 
Figure  5.  Specificity  of immunoprecipitation  of Ibl/3 moieties. Immu- 
noprecipitation  of  biosynthetically labeled proteins in culture supernatant 
of LPS-stimulated  human monocytes was carried out in the presence of 
no addition  (hnes 1 and 4), 6/~g of unlabeled mature IL-I~ (amino acids 
117-269) (lanes 2 and 5),  or 18 ~g of unlabeled  MBP-Ibl~ propeptide 
(amino acids 2-116, containing "~6/~g of propeptide). The antibodies used 
were rabbit anti-MBP-Ibl~ propeptide (lanes 1-3) and anti-mature  IblB 
(lanes 4-6). Samples were analyzed by SDS-PAGE and fluorography. This 
gd was exposed to film for 3 wk. 
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Figure  6.  Processing of biosynthetically  labeled precursor IL-1/3. Cul- 
ture supernatants  (lanes I-6) and cell lysates (lanes 7-12) of biosyntheti- 
caUy  labeled LPS-stimulated human monocytes were collected at 1 h (lanes 
I, 4,  7, and 10), 2 h (lanes 2, 5, 8, and 11), and 4 h (lanes 3, 6,  9, and 
12) after changing into unlabeled medium. The samples were immuno- 
precipitated with either  anti-MBP-IL-1B propeptide  (lanes 1-3 and 7-9) 
or anti-mature Ibl/3 (lanes 4-6 and 10-12). Immunoprecipitates were ana- 
lyzed by SDS-PAGE  and fluorography.  This gel was exposed to film for 1 wk. able at limiting antibody dilutions (in Fig. 5, compare lanes 
1 and 2 to lanes 4 and 6).  This may reflect a low affinity 
of anti-mature IL-I~ antibodies for precursor IL-1B, as has 
been noted previously (12, 13). 
A band of "~43 kD was found in immunoprecipitates of 
culture supernatants and, to a much lesser extent, cell lysates. 
This band appeared  with all the antibodies used, and was 
not competed out by unlabeled mature IL-1/3 or MBP-IL-1B 
propeptide  (Fig.  5),  suggesting  that  this  protein  binds 
nonspecifically to antibodies.  This unexplained 43-kD band 
is also evident in previous reports of IL-I~ processing (9, 
10,  14). 
Accumulation of lL-lfl Propeptide in Culture Medium and Cell 
Lysates.  To follow the course of precursor IL-I~ processing 
and production of propeptide moieties, pulse-chase experi- 
ments were conducted. As shown in Fig. 6, both the pre- 
dominant 14-kD IL-1/~ propeptide and the 17.5-kD propep- 
tide accumulate in culture medium over time (lanes 1-3). As 
demonstrated by others (11, 13, 14), mature IL-I~ also ac- 
cumulates in culture medium (lanes 4-6). Smaller amounts 
of propeptides and mature IL-I~ are also seen in cell lysates. 
Intracellularly,  the 35-kD precursor appears to remain rela- 
tively constant (better seen on shorter exposures) but precursors 
of '~29- and 31-kD decrease. The results do not distinguish 
which size of precursor IL-1/3 gives rise to mature IL-1/3 and 
IL-1B propeptide, and may reflect a complex relationship be- 
tween precursors  and products. 
Discussion 
We report here the synthesis of recombinant human IL- 
1B propeptide (Ala2-Asp116), the production of antibodies 
which specifically react with this propeptide, and the immu- 
noprecipitation by these antibodies of two unique proteins 
from human monocytes stimulated to synthesize and process 
precursor IL-I~. The larger of these two proteins migrates 
on SDS-PAGE with a mobility almost identical to that of 
mature 17.5-kD IL-I~, but is dearly not mature IL-I~ be- 
cause the specific antibody does not bind mature IL-I~. This 
protein is almost certainly bona fide IL-1B propeptide, the 
NH2-terminal product of the ICE which cleaves prolL-l~ 
between Asp  116 and Ala  117. To our knowledge, this is the 
first demonstration of the existence of the intact IL-1B propep- 
tide in vitro. 
Schmidt and Bomford (9) did identify an 18-kD biosyn- 
thetically labeled protein from stimulated monocytes, using 
antibodies against amino acids 1-15 of precursor IL-1/3. How- 
ever, since antibodies against other short synthetic peptides 
from the NH2-terminal region (amino acids 17-32, 43-54, 
and 89-100) failed to detect this protein, they concluded that 
it was not derived from the NH2 terminus of precursor IL- 
1/3. It is possible that antibodies against most of the 15-amino 
acid synthetic peptides failed to react with intact IL-1/3  propep- 
tide because of conformational differences. The peptides used 
successfully in the present study for production of anti-IL- 
1~/propeptide antibodies were nearly twice as long as those 
described above. Other studies (10-14) of IL-1B processing 
have not been designed to address the fate of the IL-13 propep- 
tide because only antibodies against mature IL-13 were used. 
A second protein of'~ 14 kD is also detected by antibodies 
against  recombinant IL-1B  propeptide, and by antibodies 
against synthetic peptide fragments 28-57 or 88-116. The sim- 
plest explanation for this smaller propeptide moiety is that 
it lacks some of the NH2-terminal residues of the 17.5-kD 
propeptide. This is an especially attractive explanation, since 
precursor IL-1B contains a second site for cleavage by ICE, 
at Asp27-Gly  2s (22). Thus, the 14-kD moiety may represent 
the Gly2S-Asp  116 fragment of the IL-1B propeptide. Since 
immunization with the synthetic peptide 1-27 did not result 
in the production of antibodies useful for immunoprecipita- 
tion, we have not further tested this hypothesis. 
The recombinant IL-13 propeptide (amino adds 2-116) mi- 
grates more slowly on SDS-PAGE than would be expected 
for a 115-amino acid protein. The monocyte-derived  propep- 
tide, demonstrated by biosynthetic labeling and immunopre- 
cipitation, migrates slightly more slowly than its recombinant 
counterpart, which could possibly be accounted for by post- 
translational modifications. The NH2-terminal portion of 
the intact precursor IL-1B is myristoylated (23), but is not 
glycosylated  (11). 
The 17.5- and 14-kD propeptide moieties do not appear 
to  be  the  result  of nonspecific  or  artifactual  cleavage of 
precursor IL-I~ by proteases, other than ICE, found in the 
culture medium or released during lysis of cells. Inclusion 
of five  additional  protease  inhibitors  (see Materials  and 
Methods) in the harvested culture medium and the cell lysis 
buffer did not result in immunoprecipitation of less mature 
IL-1B or propeptide moieties (experiments not shown). It 
is also unlikely that the 17.5- and 14-kD propeptide moieties 
are a result of toxic cell damage from the high concentration 
of LPS used in these experiments. In separate experiments 
(not shown), both mature IL-1/3 and IL-1B propeptide in- 
creased in culture supernatants with increasing concentrations 
of LPS from 1 ng/ml through 10 #g/ml, while the amount 
of intracdlular precursor was already maximum at 1 ng/ml 
LPS. Furthermore, increasing concentrations of LPS did not 
result in increasing amounts of precursor IL-1/3 being released 
into the supernatant, which could be a marker for cell damage. 
The band intensities of IL-I~ propeptide moieties which 
are detected at the end of 4 h of biosynthetic labeling, or 
which accumulate during a chase, seem to be less than would 
be expected if the propeptide(s) persists in a 1:1 relationship 
with mature IL-1/~. The fluorographic technique used here 
tends to underestimate proteins which contain less radiolabel 
or are present in smaller amounts (24). Therefore, separate 
experiments were performed for the purpose of estimating 
the relative amounts of precursors and products. Using a Phos- 
phorlmager, the relative band volumes of intracellular  35- 
kD precursor to extracellular  mature IL-1B to extracellular 
14-kD propeptide were roughly 100:10:1. Correcting for me- 
thionine content (11:6:3, respectively) results in an approxi- 
mate molar ratio of 27:5:1. Since IL-I~ propeptide(s) should 
be initially produced in 1:1 relationship with mature IL-/3, 
it appears that the propeptide moieties are degraded faster 
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beled 17.5 kD and 14 kD IL-1{3 propeptide moieties do ac- 
cumulate in pulse-chase experiments does suggest that a pool 
of IL-1/3 propeptide may exist in vivo. 
These results lead us to speculate that the NHrterminal 
portion of precursor IL-1/3 serves functions other than ren- 
dering the precursor inactive.  The precedent is established 
in vertebrate biology for two or more portions of a cleaved 
precursor protein to serve different roles. For example, com- 
plement components C3 and C5 are cleaved to form C3a and 
C3b,  C5a and  C5b,  which  have different effector roles in 
the complement cascade (25); procollagen is cleaved to form 
structural collagen, and noncollagenous carboxypeptide and 
aminopeptide fragments which modulate collagen synthesis 
(26, 27); and pro-opiomdanocortin is cleaved to form several 
peptide hormones (28). The apparent distribution of IL-1B 
propeptide moieties in both the intraceUular  and extracel- 
lular compartments raises interesting hypotheses concerning 
possible roles in regulating the processing of IL-1B, modu- 
lating  the  activity of mature IL-1/$,  or functioning  as an 
independent cytokine. The recent discovery that overexpression 
of ICE induces apoptosis in fibroblast call line (29) suggests 
the exciting possibility that the IL-1/3 propeptide could play 
a role in programmed  death of monocytes.  The  ability to 
produce reasonable quantities of purified recombinant propep- 
tide should allow investigation  of these possibilities. 
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